Cancer Family
Digestive System Neuroendocrine Neoplasm
CI-CAN-00000164Explore in graph →
Non-malignant76 active trials2 evidence items
- NCIt
- C27721
Loading cancer entity…
Cancer Family
CI-CAN-00000164Explore in graph →
Clinical trials
295 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 144 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05997056 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | completed | Phase 2 | 12 | Aadi Bioscience, Inc.INDUSTRY | 1 | Aug 25, 2026 |
| clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03980925 | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | completed | Phase 2 | 37 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03722511 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | completed | Phase 2 | 10 | Lowell Anthony, MDOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00001191 | The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | completed | Phase 2 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT01121562 | Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00602082 | Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 84 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00027638 | Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002470 | Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors | completed | Phase 2 | — | Mid-Atlantic Oncology ProgramOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00017199 | PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00055809 | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00434109 | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 14, 2012 | clinicaltrials |
| NCT00004910 | Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction | completed | Phase 1 / Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials